EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis

Jaime Fernández-Bravo-Rodrigo, Iván Cavero-Redondo, Maribel Lucerón-Lucas-Torres, Irene Martínez-García, Amparo Flor-García, Dolores Barreda-Hernández, Carlos Pascual-Morena

European Journal of Pharmacology · 2024

DOI: 10.1016/j.ejphar.2024.176702 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Jaime Fernández-Bravo-Rodrigo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, 16071, Spain; Pharmacy Service, Hospital Virgen de la Luz, 16002, Cuenc…. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: Universidad de Castilla-La Mancha, Spain Ministry of Science Innovation and Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Migraine is a common and disabling primary headache disorder. Several drugs targeting calcitonin gene-related peptide (CGRP), such as erenumab (an anti-CGRP receptor mAb), have been developed recently. However, the real-world effects of erenumab are not well understood. OBJECTIVE: To assess the clinical effectiveness and safety of erenumab for reducing migraine intensity and frequency in the real world. METHODS: A systematic search of PubMed, Scopus, Web of Science and the Cochrane Library was conducted from inception to December 2023. Studies estimating the real-world effect of erenumab on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6), number of days in medication (NDM), acute monthly intake (AMI), pain intensity (PI) and safety outcomes were included. Meta-analyses of proportions or mean differences were performed. RESULTS: Fifty-three studies were included. At 3-months, the effect was -7.18 days for MMD, -6.89 days for MHD, -6.97 for HIT-6, -6.22 days for NDM, -15.75 for AMI, and -1.71 for PI. Generally, the effect at 6- and 12-months increased slightly and gradually. The MMD/MHD response rates revealed that approximately one-third of patients exhibited a response greater than 30%, while one-sixth demonstrated a response exceeding 50%. Additionally, 3-4% of patients achieved a response rate of 100%. Adverse event rates were 0.34 and 0.43 at 6- and 12-months, respectively. CONCLUSION: This study provides strong evidence of the effectiveness and safety of erenumab in the real world; to our knowledge, this is the first real-world meta-analysis specific to erenumab. Erenumab represents a solid therapeutic option for physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHumansTreatment Outcome

Stichwörter der Autor:innen

Biological therapyMeta-analysisMigraineMonoclonal antibodyNeurologySystematic review

Substanzen

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, 16071, Spain; Pharmacy Service, Hospital Virgen de la Luz, 16002, Cuenca, Spain; Pharmacy Service. Hospital Virgen del Castillo, 30510, Yecla…
  • Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, 3460000, Chile. Electronic address: ivan.cavero@uclm.es.
  • Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, 16071, Spain. Electronic address: mariaisabel.luceron@uclm.es.
  • Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, 16071, Spain. Electronic address: irene.mgarcia@uclm.es.
  • Pharmacy Service, Hospital Virgen de la Luz, 16002, Cuenca, Spain. Electronic address: amparof@sescam.jccm.es.
  • Pharmacy Service, Hospital Virgen de la Luz, 16002, Cuenca, Spain. Electronic address: dbarreda@sescam.org.

Förderung

  • Universidad de Castilla-La Mancha
  • Spain Ministry of Science Innovation and Universities

Zitieren

APA

Fernández-Bravo-Rodrigo, J., Cavero-Redondo, I., Lucerón-Lucas-Torres, M., Martínez-García, I., Flor-García, A., Barreda-Hernández, D., & Pascual-Morena, C. (2024). Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176702

Vancouver

Fernández-Bravo-Rodrigo J, Cavero-Redondo I, Lucerón-Lucas-Torres M, Martínez-García I, Flor-García A, Barreda-Hernández D, et al. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176702

BibTeX
@article{FernndezBravoRodrigo2024,
  author = {Fernández-Bravo-Rodrigo, Jaime and Cavero-Redondo, Iván and Lucerón-Lucas-Torres, Maribel and Martínez-García, Irene and Flor-García, Amparo and Barreda-Hernández, Dolores and Pascual-Morena, Carlos},
  title = {Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis},
  journal = {European Journal of Pharmacology},
  year = {2024},
  doi = {10.1016/j.ejphar.2024.176702}
}
Kostenlos starten →